
Claritin is owned by Bayer AG, a publicly traded German life sciences company listed on the Frankfurt Stock Exchange (BAYN). Bayer acquired the brand in October 2014 as part of its $14.2 billion purchase of Merck and Co.'s consumer care business. The active ingredient, loratadine, was originally developed by Schering-Plough and received FDA approval in 1993.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Claritin | Bayer AG | Wholly owned |
Loratadine, the molecule behind Claritin, was synthesized by Schering-Plough Corporation scientists in the early 1980s. The compound was designed to block histamine-1 receptors without crossing the blood-brain barrier in significant amounts, which meant it could treat allergy symptoms without the heavy sedation associated with first-generation antihistamines such as diphenhydramine.
The FDA approved Claritin tablets on April 12, 1993, under NDA 019658 for the treatment of seasonal allergic rhinitis and chronic urticaria. The prescription product became one of the largest-selling antihistamines in the world. Schering-Plough expanded the line with Claritin-D, a combination of loratadine and the decongestant pseudoephedrine, and with syrup formulations for children.
Through the late 1990s, Claritin was among the most heavily advertised prescription drugs in the United States. The brand's fate changed when its market exclusivity approached expiration. In 2001 and 2002, health insurers, led by WellPoint Health Networks, petitioned the FDA to move the second-generation antihistamines Claritin, Zyrtec, and Allegra to over-the-counter status, arguing the drugs were safe for self-medication and that prescription status inflated costs. The FDA approved Claritin for nonprescription use in November 2002, and OTC sales began in December 2002. Claritin was the first of the three major second-generation antihistamines to make the switch.
The OTC transition was commercially significant. Claritin moved from a prescription drug earning roughly $3 billion at its peak to a consumer brand competing on retail shelves against private-label loratadine. Schering-Plough extended the franchise with RediTabs orally disintegrating tablets, Liqui-Gels, Children's Claritin chewables and syrup, and ClariSpray nasal spray.
In November 2009, Merck and Co. completed its acquisition of Schering-Plough for approximately $41 billion, and Claritin became a Merck brand. Merck's consumer strategy did not last long. In May 2014, Merck announced an agreement to sell its entire consumer care business to Bayer for $14.2 billion, a deal that closed on October 1, 2014. Claritin, along with Coppertone, MiraLAX, and Dr. Scholl's, transferred to Bayer's Consumer Health division.
Under Bayer, the Claritin portfolio has continued to expand. Bayer markets Claritin tablets, RediTabs, Liqui-Gels, Children's Claritin, Claritin-D, and ClariSpray in the United States, and ClariCare, a plant-based allergy product, in European markets. As of late 2026, the FDA's records show 34 approved supplements to the original Claritin NDA, with labeling revisions approved as recently as September 2026, confirming the brand remains actively marketed.
Who owns Bayer?
Bayer AG is publicly traded on the XETRA/Frankfurt Stock Exchange under ticker BAYN with no controlling shareholder. Institutional investors including BlackRock, Vanguard Group, and other large investment management firms collectively hold the majority of outstanding shares. No individual, family, or private equity firm holds a controlling interest. The company operates under German corporate governance with a two-tier board system.
What is Bayer's annual revenue?
Bayer reported Group sales of EUR 45.575 billion for fiscal year 2025, a decrease of 2.2% on a reported basis but an increase of 1.1% on a currency- and portfolio-adjusted basis. EBITDA before special items was EUR 9.669 billion (down 4.5%), and net income was EUR -3.620 billion due to high special charges for litigation. For Q2 2026, Group sales were EUR 10.872 billion (up 2.2% adjusted), and the company confirmed its currency-adjusted outlook for 2026.
What brands does Bayer own?
Bayer owns pharmaceutical brands including Xarelto, Eylea, Nubeqa, and Kerendia; consumer health brands including Aspirin, Aleve, Claritin, Coppertone, and Bepanthen; and agricultural brands including Roundup, DeKalb, Climate FieldView, Preceon Smart Corn System, and Plenexos. The company also owns Bayer 04 Leverkusen football club, which won its first Bundesliga title in the 2023/24 season.
What is the Roundup litigation at Bayer?
The Roundup litigation involves claims alleging that Monsanto's Roundup herbicide causes cancer due to glyphosate exposure, inherited through Bayer's 2018 acquisition of Monsanto. In 2025, Monsanto agreed with leading plaintiff law firms on a proposed nationwide class settlement establishing a long-term claims program funded by declining capped annual payments for up to 21 years. In June 2026, the U.S. Supreme Court ruled 7:2 in the Durnell case that FIFRA preempts state-law failure-to-warn claims, which should result in the dismissal of current warnings-based claims and foreclose future claims.
Who is the CEO of Bayer?
Bill Anderson has served as CEO of Bayer AG since June 2023. He has led a significant turnaround focused on four strategic priorities: rejuvenating the Pharmaceuticals pipeline, executing the Crop Science Five-Year Framework, significantly containing litigation by the end of 2026, and driving efficiency through a new operating model. Under his leadership, Bayer has reduced net financial debt and headcount while advancing its pipeline.
Is Bayer publicly traded?
Yes, Bayer AG is publicly traded on the XETRA/Frankfurt Stock Exchange under the ticker symbol BAYN. The company has been publicly traded since its re-establishment in 1951 and is a component of the DAX 40 index, Germany's premier stock market index. The proposed dividend for FY2025 is EUR 0.11 per share, maintained at a reduced level to prioritize debt reduction.
What is the Monsanto acquisition and why is it controversial?
Bayer acquired Monsanto in 2018 for approximately $63 billion, making it the world's largest seed and agrochemical company. The acquisition has been widely criticized because it brought approximately 100,000+ Roundup (glyphosate) cancer claims, PCB litigation, and a massive debt burden. The litigation has cost Bayer billions in settlements and special charges, and the company's stock price and dividend have been significantly impacted. The acquisition is considered one of the most value-destructive deals in pharmaceutical industry history.
What is Bayer's sustainability strategy?
Bayer's sustainability strategy is aligned with its mission "Health for all, Hunger for none" and includes commitments to achieve Net Zero GHG emissions by 2050 (SBTi-approved), reduce water use per kilogram of crop by 25% by 2030 for smallholder rice farmers, reduce water withdrawals in Pharmaceuticals and Consumer Health by 20% by 2030, transition all Consumer Health products to 100% recycle-ready packaging, and improve access to medicine and self-care globally. The company also invests in regenerative agriculture with a target of 250,000 tons of wheat from regenerative farming.
In the early 2000s, Schering-Plough entered an FDA consent decree covering manufacturing deficiencies at its New Jersey facilities, which at the time produced Claritin. The 2002 decree required the company to pay $500 million and upgrade quality systems across plants in Kenilworth and Manati, Puerto Rico. The action concerned manufacturing process controls rather than Claritin's safety profile, and the facilities' remediation was completed under FDA oversight before the Merck acquisition.
Claritin-D contains pseudoephedrine, which is subject to purchase restrictions under the Combat Methamphetamine Epidemic Act of 2005. Retailers must keep the product behind the pharmacy counter, limit purchase quantities, and record buyer identification. These rules reduce sales volume for all pseudoephedrine products, including Claritin-D, without implying any defect in the product itself.
The brand has not faced a major product safety recall in recent years. Generic loratadine has occasionally been subject to recalls by third-party manufacturers, but these events do not involve Bayer's branded product. As of November 2026, no FDA enforcement action or consumer safety recall specific to branded Claritin has been reported.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Opella | France | 1996 | Mass market | Global | All Genders | |
| Kenvue | USA | 1995 | Mass market | Global | All Genders | |
| Haleon | United Kingdom | 2022 | Mass market | Global | All-ages |
Healthcare PharmaceuticalsOwned by Opella
Over-the-counter allergy relief brand containing fexofenadine, originally developed by Hoechst Marion Roussel and approved by the FDA in 1996. Owned since April 2025 by Opella, the consumer healthcare company carved out of Sanofi and controlled by Clayton, Dubilier and Rice.
Healthcare PharmaceuticalsOwned by Kenvue
Over-the-counter allergy relief brand containing cetirizine hydrochloride, developed by UCB Pharma and marketed in the United States since 1995. Owned by Kenvue Inc. since its 2023 spinoff from Johnson and Johnson. Kenvue is the world's largest pure-play consumer health company by revenue, with $15.1 billion in net sales for fiscal year 2025.
Healthcare PharmaceuticalsOwned by Haleon plc
Consumer healthcare brand and company name of the world's largest pure-play consumer health business, owner of Sensodyne, Advil, Panadol, and Centrum.
Market Positioning: Claritin competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Bayer AG, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Opella
Over-the-counter allergy relief brand containing fexofenadine, originally developed by Hoechst Marion Roussel and approved by the FDA in 1996. Owned since April 2025 by Opella, the consumer healthcare company carved out of Sanofi and controlled by Clayton, Dubilier and Rice.
Allegra is privately owned, unlike Claritin which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
Over-the-counter allergy relief brand containing cetirizine hydrochloride, developed by UCB Pharma and marketed in the United States since 1995. Owned by Kenvue Inc. since its 2023 spinoff from Johnson and Johnson. Kenvue is the world's largest pure-play consumer health company by revenue, with $15.1 billion in net sales for fiscal year 2025.
Zyrtec is privately owned, unlike Claritin which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
Band-Aid is privately owned, unlike Claritin which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Pharmavite LLC
America's number-one-selling vitamin brand, owned by Pharmavite LLC, a subsidiary of Japan's Otsuka Pharmaceutical since 1989.
Nature Made is privately owned, unlike Claritin which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Claritin which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Claritin which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.